Cell And Gene Therapies – U.S. Payer Trends

As cell and gene therapies expand beyond rare diseases into broader patient populations, the pressure to secure timely, sustainable market access has never been greater. Payers are paying closer attention, setting higher evidence bars, and developing more structured processes for evaluating these high-cost, high-value therapies. Understanding exactly what they expect, and when, is now a critical factor in commercial success.

Based on interviews with U.S. payers in active decision-making roles across national and regional health plans and integrated delivery networks, this webinar offers insights into how payer mindsets toward CGTs are shifting, what distinguishes national from regional payer approaches, and how to structure early engagement so your evidence package meets the right standards at the right time.

Coverage processes, decision-making timelines, and post-approval requirements are all evolving, and the organizations that get ahead of these changes will be better positioned to convert clinical success into market uptake. Whether you are in late-stage development or actively navigating launch, the actionable, data-driven strategies shared here will help you build a market access plan grounded in what payers actually need.

Watch the full webinar recording now to translate U.S. payer expectations into a stronger, more competitive access strategy.